Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency. Biosimilars are expected to be a cost-effective alternative to the high-priced branded biologics, offering significant and much-needed cost savings to both payers and the patients. Hence, the providers are more likely to adopt biosimilars as a “reference […]Read More
1. Ultragenyx and Kyowa Kirin’s Crysvita (burosumab) Receive the US FDA’s Approval for the Treatment of Tumor-Induced Osteomalacia Published: Jun 19, 2020 | Tags: Ultragenyx, Kyowa Kirin, Crysvita, burosumab, Receives, US, FDA, Approval, Treatment, Tumor-Induced Osteomalacia 2. Pfizer and Sangamo’s Giroctocogene Fitelparvovec (SB-525) Demonstrate Positive Effect in P-I/II Alta Study for Hemophilia A Published: Jun 18, 2020 […]Read More
Shots: The launch of the Samsung Health Monitor application follows MFDS’ clearance in April. Galaxy Watch Active2 users can measure and track their blood pressure via the Samsung Health Monitor App anytime, anywhere in South Africa For measuring the blood pressure, users must have the app installed on both the Galaxy Watch Active2 and the […]Read More
Amgen Signs a Partnership with Adaptive Biotechnologies to Develop for COVID-19 Published: Apr 09, 2020 | Tags: Amgen, Adaptive Biotechnologies, Develop, Abs, COVID-19 2. Samsung Biologics Signs an Agreement with Vir Biotechnology to Develop Abs for COVID-19 Published: Apr 09, 2020 | Tags: Samsung Biologics, Agreement, Vir Biotechnology, Abs, COVID-19 3. Abbott’s TriClip Transcatheter Tricuspid […]Read More
Copyright ©2021 PharmaShots | Powered by Octavus Consulting
